Adma Biologics Stock Sinks As Market Gains Heres Why
ADMA Stock | USD 21.83 0.01 0.05% |
About 60% of ADMA Biologics' investor base is looking to short. The analysis of the overall investor sentiment regarding ADMA Biologics suggests that many traders are alarmed. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
ADMA |
In the most recent trading session, Adma Biologics closed at 19.50, indicating a -1.37 percent shift from the previous trading day.
Read at zacks.com
ADMA Biologics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards ADMA Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ADMA Biologics Fundamental Analysis
We analyze ADMA Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
ADMA Biologics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
ADMA Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADMA Biologics stock to make a market-neutral strategy. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics with similar companies.
Peers
ADMA Biologics Related Equities
FATE | Fate Therapeutics | 18.28 | ||||
XFOR | X4 Pharmaceuticals | 11.43 | ||||
CRBU | Caribou Biosciences | 8.91 | ||||
MCRB | Seres Therapeutics | 4.55 | ||||
SANA | Sana Biotechnology | 4.08 | ||||
IBIO | Ibio | 3.54 | ||||
TFFP | Tff Pharmaceuticals | 3.33 | ||||
CDTX | Cidara Therapeutics | 3.11 | ||||
ETNB | 89bio | 2.70 | ||||
ANEB | Anebulo Pharmaceuticals | 2.14 | ||||
VXRT | Vaxart | 1.67 | ||||
PLRX | Pliant Therapeutics | 1.42 | ||||
STOK | Stoke Therapeutics | 1.19 | ||||
PLX | Protalix Biotherapeutics | 0.60 | ||||
AKBA | Akebia Ther | 0.49 | ||||
INMB | INmune Bio | 0.20 | ||||
BCRX | BioCryst Pharmaceuticals | 0.13 | ||||
RCUS | Arcus Biosciences | 0.06 | ||||
ATRA | Atara Biotherapeutics | 0.65 | ||||
ANTX | AN2 Therapeutics | 1.44 | ||||
MDGL | Madrigal Pharmaceuticals | 1.57 | ||||
ACLX | Arcellx | 2.08 | ||||
TNXP | Tonix Pharmaceuticals | 5.00 |
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Equity Valuation Check real value of public entities based on technical and fundamental data |